Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up

Conduit, C; Koh, TT; Hofman, MS; Toner, GC; Goad, J; Lawrentschuk, N; Tai, KH; Lewin, JH; Tran, B

Author(s): Conduit, C; Koh, TT; Hofman, MS; Toner, GC; Goad, J; Lawrentschuk, N; Tai, KH; Lewin, JH; Tran, B;
Details: Publication Year 2022-10-08,Volume 22,Issue #1,Page 58
Journal Title: Cancer Imaging
Abstract: BACKGROUND: Survivors of testicular cancer may experience long-term morbidity following treatment. There is an unmet need to investigate techniques that can differentiate individuals who need additional therapy from those who do not. 2-(18)fluoro-deoxy-D-glucose (FDG) positron emission tomography (PET) with computerised tomography (CT) may be helpful in select settings and may be used outside of current evidence-based recommendations in real-world practice. METHODS: A institutional FDG-PET/CT database of scans performed between 2000 and 2020 for adults with testicular seminoma was interrogated. Endpoints of interest included the positive (PPV) and negative (NPV) predictive value of FDG-PET/CT for identifying active seminoma (defined by progressive radiology, response to treatment or biopsy); or no active seminoma within 24-months for patients with stage 1 and advanced seminoma. An exploratory analysis examining predictive role of SUV(max) was also performed. RESULTS: 249 patients met eligibility criteria for the analysis, including 184 patients with stage 1 and 77 patients with advanced testicular seminoma. Of 193 FDG-PET/CT performed in stage 1 seminoma with available follow-up data, 79 were performed during active surveillance. 18 (23%) of these were positive, all of which had confirmed recurrent seminoma (PPV 100%). Of 45 negative FDG-PET/CT during active surveillance, 4 recurrences developed corresponding to a NPV 91%. When clinical suspicion precipitated FDG-PET/CT (n = 36): PPV 100%, NPV 86%. Of 145 FDG-PET/CT in advanced seminoma with available follow-up data, 25 (17%) were performed at baseline (within 2 months of diagnosis), 70 (48%) post-treatment for evaluation of treatment response and 50 (34%) during follow-up following prior curative treatment. 10 (14%) post-treatment FDG-PET/CT were positive corresponding to a PPV 60%. Of 46 negative FDG-PET/CT, 5 recurrences occurred (NPV 89%). During follow-up after prior curative treatment, 24 (50%) FDG-PET/CT were positive corresponding to a PPV 83%; of 20 negative FDG-PET/CT, 1 recurrence occurred, NPV 95%. When clinical suspicion indicated FDG-PET/CT (n = 36): PPV 100%, NPV 94%. CONCLUSION: FDG-PET/CT offers high PPV for identifying seminoma and accurately predicts non-recurrence across a clinically relevant 24-months. Notably, FDG-PET/CT may prevent unnecessary treatment in 45% of patients undergoing investigation for clinical suspicion of recurrence during follow-up of advanced seminoma. The use of FDG-PET/CT in selected patients now, may help prevent unnecessary treatment of people with testicular seminoma.
Publisher: BMC
Keywords: Biomarkers; PET-CT scan; Seminomas; Testicular neoplasm; cancer survivors
Research Division(s): Personalised Oncology
PubMed ID: 36209121
Publisher's Version: https://doi.org/10.1186/s40644-022-00496-w
Open Access at Publisher's Site: https://doi.org/10.1186/s40644-022-00496-w
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-02-02 02:06:18

Last Modified: 2023-02-02 02:08:16